Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 167
Filter
1.
ESMO Open ; 7(1): 100338, 2022 02.
Article in English | MEDLINE | ID: mdl-34920290

ABSTRACT

BACKGROUND: Vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors (TKIs) are widely used in cancer treatment and burdened by cardiovascular toxicity. The majority of data come from clinical trials, thus in selected populations. The aim of our study is to evaluate the cardiotoxicity profile of VEGFR-targeted TKIs and the impact of cardiovascular risk factors in a real-life population. PATIENTS AND METHODS: In this cohort, population-based study, patients treated with VEGFR-targeted TKIs, bevacizumab and trastuzumab between 2009 and 2014 were analyzed. A multi-source strategy for data retrieval through hospital, pharmaceutical and administrative databases of the Lombardy region, Italy, has been adopted. The primary endpoint was to determine the incidence and type of major adverse cardiovascular events (MACEs) along with their temporal trend. The secondary endpoint was to define the impact of cardiovascular risk factors in the occurrence of MACEs. RESULTS: A total of 829 patients were treated with VEGFR-targeted TKIs. Eighty-one MACEs occurred in the first year of follow-up [crude cumulative incidence (CCI): 9.79%] mainly consisting of arterial thrombotic events (ATEs, 31 events, CCI: 3.99%), followed by rhythm disorders (22 events, CCI: 2.66%), pulmonary embolisms and heart failures (13 events each, CCI: 1.57%). While the incidence of most MACEs showed a plateau after 6 months, ATEs kept increasing along the year of follow-up. Hypertension and dyslipidemia were associated with an increase in risk of ATEs [relative risk difference (RRD) +209.8% and +156.2%, respectively], while the presence of previous MACEs correlated with a higher risk of all MACEs in multivariate analysis (RRD 151.1%, 95% confidence interval 53.6% to 310.3%, P < 0.001). CONCLUSIONS: MACEs occur in a clinically significant proportion of patients treated with VEGFR-targeted TKIs, with ATEs being predominant, mainly associated with hypertension and dyslipidemia. A clinical algorithm for effective proactive management of these patients is warranted.


Subject(s)
Receptors, Vascular Endothelial Growth Factor , Vascular Endothelial Growth Factor A , Algorithms , Cardiotoxicity/epidemiology , Cardiotoxicity/etiology , Humans , Protein Kinase Inhibitors/adverse effects
2.
Eur Rev Med Pharmacol Sci ; 25(23): 7218-7222, 2021 12.
Article in English | MEDLINE | ID: mdl-34919220

ABSTRACT

OBJECTIVE: Anti-COVID-19 vaccines were mainly associated with non-serious adverse events (AEs), whose prevalence was reported to be up to 70% in healthcare workers (HCWs). This may lead to sick leave requests, but this impact has never been quantified. This study aimed to investigate the absence from work among HCWs following anti-COVID-19 vaccination. Its association with age and previous COVID-19 infection was also assessed. PATIENTS AND METHODS: This is a retrospective observational cross-sectional study on administrative data about sick leave requests after anti-COVID-19 vaccination. All the HCWs employed at the Niguarda Hospital (Milan, Italy) who received the vaccine from December 27, 2020 to February 28, 2021 were included. RESULTS: In total, 4,088 HCWs received the first dose of the vaccine and 4,043 completed the vaccination cycle. After the first injection, 1.6% of HCWs requested sick leave, while after the second injection, the number of requests significantly increased (+6.1%, p<0.001). A significant increase in sick leave was detected for those who have had SARS-CoV-2 infection after the first injection (+2.3%, p<0.001). After the second dose, a significant increase in sick leave was observed in the 20-30-year-old group compared to >30 years (+3.6%, p=0.017), if HCWs without a history of SARS-CoV-2 infection were considered. CONCLUSIONS: The requests for sick leave among HCWs following the anti-COVID-19 vaccine were limited and higher after the second injection. This may help the management of the human resources when the large-scale administration of the anti-COVID-19 vaccines will involve other categories of workers.


Subject(s)
BNT162 Vaccine/administration & dosage , COVID-19/prevention & control , Health Personnel/statistics & numerical data , Sick Leave/statistics & numerical data , Adult , Age Factors , BNT162 Vaccine/adverse effects , Cross-Sectional Studies , Female , Humans , Italy/epidemiology , Male , Middle Aged , Prevalence , Retrospective Studies , Young Adult
3.
J Biol Regul Homeost Agents ; 35(3): 847-863, 2021.
Article in English | MEDLINE | ID: mdl-34155874

ABSTRACT

Respiratory infections (RI) significantly burden patients, their families, and society. Respiratory infection recurrence (RRI) usually depends on a defect of the immune response, which can be more or less transient and/or selective. In particular, children, older people, heavy smokers, and patients with chronic diseases, characterized by an inadequate immune response, may be at risk of developing RRI. In this context, OM- 85 could represent a valuable option in the management of RRI. OM-85 is a bacterial lysate containing the extracts of some common pathogens, including Branhamella catarrhalis, Klebsiella pneumoniae, Klebsiella ozaenae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, and Staphylococcus aureus. Methodologically rigorous studies have documented the mechanism of action, efficacy, and safety of OM-85. OM-85 enhances the natural and acquired immune response through multifaceted mechanisms. Substantial evidence has shown that OM-85 can prevent respiratory infections, reduce the number of COPD exacerbations, and shorten the disease duration at home or in hospital. OM-85 can enhance the effectiveness of the 'flu vaccination without affecting the vaccine tolerability. The preventive use of OM-85 can reduce the use of antibiotics, contributing to contrast antibiotic resistance and saving the high cost of chronic respiratory diseases. Further studies should define the ideal candidate to OM-85 treatment.


Subject(s)
Klebsiella , Respiratory Tract Infections , Aged , Child , Humans , Moraxella catarrhalis , Respiratory Tract Infections/prevention & control , Streptococcus pneumoniae
4.
ESMO Open ; 6(3): 100156, 2021 06.
Article in English | MEDLINE | ID: mdl-34044286

ABSTRACT

The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to anti-epidermal growth factor receptor (EGFR) antibodies. In the last decades, several investigational attempts failed in directly targeting RAS mutations, thus RAS was historically regarded as 'undruggable'. Recently, novel specific KRASG12C inhibitors showed promising results in different solid tumors, including mCRC, renewing interest in this biomarker as a target. In this review, we discuss different strategies of RAS targeting in mCRC, according to literature data in both clinical and preclinical settings. We recognized five main strategies focusing on those more promising: direct RAS targeting, targeting the mitogen-activated protein kinase (MAPK) pathway, harnessing RAS through immunotherapy combinations, RAS targeting through metabolic pathways, and finally other miscellaneous approaches. Direct KRASG12C inhibition is emerging as the most promising strategy in mCRC as well as in other solid malignancies. However, despite good disease control rates, tumor response and duration of response are still limited in mCRC. At this regard, combinational approaches with anti-epidermal growth factor receptor drugs or checkpoint inhibitors have been proposed to enhance treatment efficacy, based on encouraging results achieved in preclinical studies. Besides, concomitant therapies increasing metabolic stress are currently under evaluation and expected to also provide remarkable results in RAS codon mutations apart from KRASG12C. In conclusion, based on hereby reported efforts of translational research, RAS mutations should no longer be regarded as 'undruggable' and future avenues are now opening for translation in the clinic in mCRC.


Subject(s)
Colonic Neoplasms , Genes, ras , Humans , Mutation
5.
Animal ; 15(2): 100113, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33573988

ABSTRACT

Antimicrobial (AM) resistance is largely acknowledged as one of the biggest global health and food safety challenges and the overuse of AMs is known to generate resistance in bacteria that may affect both animals and humans. Poultry meat is the second most-produced meat in the European Union and in recent years consumers are becoming more concerned about food safety, traceability, and animal welfare in poultry rearing system, increasingly requiring meats from broilers reared without AMs. In the present study, we performed RNA sequencing to analyze 64 liver and 54 muscle transcriptomic profiles in broilers reared without treatment or treated with different classes of AMs. Moreover, we validated the most differentially expressed genes among the treated groups to detect putative novel biomarkers able to discriminate meats of broilers reared without AMs. The PDK4, IGFBP1, and RHOB genes were identified as putative novel hepatic biomarkers, discriminating broilers treated with AMs compared to broilers reared without treatments. The whole transcriptome changes revealed the liver as a valuable target organ for AM administration screening. In addition, our results suggest a leading effect of the coccidiostat when associated with AMs, influencing several biological processes. Our study showed that RNA sequencing is a powerful and valuable method to detect aberrant regulated genes and to identify biomarker candidates for AM misuse detection in farm animals. Further validation on larger sample size and a wider spectrum of AMs are needed to confirm the viability of the aforementioned biomarkers in poultry population.


Subject(s)
Anti-Infective Agents , Chickens , Animals , Biomarkers , Chickens/genetics , Meat/analysis , RNA
6.
Eur Rev Med Pharmacol Sci ; 25(24): 7985-7996, 2021 12.
Article in English | MEDLINE | ID: mdl-34982462

ABSTRACT

OBJECTIVE: This study aimed to improve the post-marketing surveillance on mRNA anti-SARS-CoV-2 vaccines, characterizing the adverse events (AEs) after the first dose of mRNA BNT162b vaccine. The associations between the AEs and individuals' characteristics were explored. PATIENTS AND METHODS: All adult healthcare workers at Niguarda Hospital (Milan, Italy) who were referred for the first dose of vaccine were offered to participate in a cross-sectional survey during the second-dose administration, between 18 January and 7 February 2021. All participants completed a questionnaire about age, gender, weight, height, medical history, concurrent therapies, employment status, previous diagnosis/testing for SARS-CoV-2 infection, and a list of 24 AEs (solicited AEs). The development of at least one solicited AEs was the main outcome. AEs were stratified by the presence of injection-site symptoms, systemic symptoms or both, and the differences between strata were assessed as a secondary outcome. Biometric data and reports of a previous diagnosis of SARS-CoV-2 infection were also explored, as predictors of the main outcome. RESULTS: 7,014 healthcare workers were included. An incidence of 3 per 10.000 persons for serious AEs following the first administration of the mRNA BNT162b vaccine was found. An association between the development of non-serious AEs with young age, female gender, low body mass index, and previous history of SARS-CoV-2 was described. CONCLUSIONS: This real-life study supported data on the safety profile of the BNT162b2 mRNA vaccine. Our findings on the associations between the development of non-serious AEs with some individual characteristics may help physicians and patients make educated and informed medical decisions towards anti-COVID-19 vaccination.


Subject(s)
BNT162 Vaccine/adverse effects , COVID-19/prevention & control , Vaccination/adverse effects , Adult , Age Factors , BNT162 Vaccine/administration & dosage , COVID-19/epidemiology , COVID-19/immunology , COVID-19/virology , Cross-Sectional Studies , Female , Health Personnel/statistics & numerical data , Humans , Male , Medical History Taking/statistics & numerical data , Middle Aged , Product Surveillance, Postmarketing/statistics & numerical data , Risk Factors , SARS-CoV-2/immunology , Sex Factors , Vaccination/statistics & numerical data
7.
Sci Rep ; 9(1): 6061, 2019 04 15.
Article in English | MEDLINE | ID: mdl-30988332

ABSTRACT

Between 2015 and the beginning of 2018 (January-March), 30 cetaceans were found stranded along the Ligurian Sea coast of Italy. Necropsies were performed in 22 cases and infectious diseases resulted the most common cause of death. Three striped dolphins, showed a severe coinfection involving the monophasic variant of Salmonella Typhimurium (Salmonella 1,4,[5],12:i:-). The isolates were characterized based on antimicrobial resistance, Multiple-Locus Variable-number tandem-repeat Analysis (MLVA) and whole-genome sequencing (WGS). All isolates demonstrated the same multidrug resistant genotype (ASSuT isolates), showed three different MLVA profiles, two of which closely related, and were identified as Sequence Type 34. Moreover, Single nucleotide polymorphisms (SNP) analysis confirmed strong correlations between two out of the three isolates. To our knowledge, S. 1,4,[5],12:i:-, one of the most common serovars in cases of human infection and food sources worldwide, has not previously been described in marine mammals, and reports of Salmonella-associated disease in free-ranging cetaceans are rare. These results highlight the role of cetaceans as sentinel species for zoonotic and terrestrial pathogens in the marine environment, suggest a potential risk for cetaceans and public health along the North Western Italian coastline and indicate cetaceans as a novel potential reservoir for one of the most widespread Salmonella serovars.


Subject(s)
Coinfection/veterinary , Salmonella Infections, Animal/microbiology , Salmonella typhimurium/genetics , Stenella/microbiology , Animals , Bacterial Typing Techniques , Coinfection/microbiology , Drug Resistance, Multiple, Bacterial/genetics , Fatal Outcome , Female , Italy , Male , Minisatellite Repeats/genetics , Salmonella typhimurium/isolation & purification
8.
Domest Anim Endocrinol ; 62: 10-15, 2018 01.
Article in English | MEDLINE | ID: mdl-28886589

ABSTRACT

The aim of this work was to study the transcriptional effects of glucocorticoids on corticosteroid hormone receptors, prereceptors (11ß-hydroxysteroid dehydrogenase 1 and 2, 11ß-HSD1 and 2), and chaperones molecules regulating intracellular trafficking of the receptors (FKBP51 and FKBP52) in thymus of veal calves. Moreover, the expression of FKBP51 and FKBP52 gene were investigated in beef cattle thymus. In the cervical thymus of veal calves, dexamethasone administration in combination with estradiol decreased FKBP51 expression (P < 0.01). The same treatment increased mineralocorticoid receptor (MR) (P < 0.01) and 11ß-HSD1 expression (P < 0.05) compared to control group in the cervical thymus of veal calves. The thoracic thymus of veal calves treated with dexamethasone and estradiol showed a decrease of FKBP51 (P < 0.05), FKBP52 (P < 0.05), glucocorticoid receptor (P < 0.05), and MR expression (P < 0.05) compared to control group in the thoracic thymus of veal calves. The gene expression of FKBP51 decreased both in cervical (P < 0.01) and thoracic thymus (P < 0.01) of beef cattle treated with dexamethasone and estradiol. In addition, also prednisolone administration reduced FKBP51 expression in the cervical thymus (P < 0.01) and in the thoracic thymus of beef cattle (P < 0.01). The gene expression of FKBP52 increased only in the cervical thymus following dexamethasone administration (P < 0.01). The decrease of FKBP51 gene expression in thymus could be a possible biomarker of illicit dexamethasone administration in bovine husbandry. Moreover, so far, an effective biomarker of prednisolone administration is not identified. In this context, the decrease of FKBP51 gene expression in thymus of beef cattle following prednisolone administration could play an important role in the indirect identification of animals illegally treated with prednisolone.


Subject(s)
Dexamethasone/pharmacology , Prednisolone/pharmacology , Tacrolimus Binding Proteins/metabolism , Thymus Gland/drug effects , Animals , Cattle , Dexamethasone/administration & dosage , Gene Expression Regulation/drug effects , Glucocorticoids/administration & dosage , Glucocorticoids/pharmacology , Male , Prednisolone/administration & dosage , RNA/genetics , RNA/metabolism , Tacrolimus Binding Proteins/genetics , Thymus Gland/metabolism
9.
J Glob Antimicrob Resist ; 10: 295-303, 2017 09.
Article in English | MEDLINE | ID: mdl-28732783

ABSTRACT

Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009. Many others, such as the newer tetracyclines, fluoroquinolones, oxazolidinones and pleuromutilins, are in various stages of development. In addition, an ongoing multicentre trial is investigating the role of combination of vancomycin or daptomycin with ß-lactam antibiotics. This review discusses the role of the newer antibiotics, reflecting the views of the 6th MRSA Consensus Conference meeting of the International Society of Chemotherapy MRSA Working Group that took place in 2016.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcal Infections/drug therapy , Anti-Bacterial Agents/pharmacology , Clinical Trials as Topic , Daptomycin/pharmacology , Daptomycin/therapeutic use , Drug Resistance, Multiple, Bacterial/drug effects , Drug Therapy, Combination , Humans , Multicenter Studies as Topic , Staphylococcal Infections/microbiology , Vancomycin/pharmacology , Vancomycin/therapeutic use , beta-Lactams/pharmacology , beta-Lactams/therapeutic use
10.
Res Vet Sci ; 104: 123-5, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26850550

ABSTRACT

Blood parasites infect all vertebrates (Clayton and Moore 1997). Avian malaria parasites (Plasmodium spp., Plasmodiidae) are cosmopolitan in their distribution and are responsible for severe diseases in domestic and wild birds.In September 2009, nine raptorial birds that either arrived recently or were maintained as permanent residents at the Safaripark Pombia (northwest Italy) showed loss of stamina, developing listlessness, anorexia and regurgitation. Within one month three animals died and were necropsied.Following the diagnosis of Plasmodium infection all other raptorial birds were treated: clinical improvement was observed in all birds, and blood smears made after one month resulted negative for parasites.


Subject(s)
Animals, Zoo , Falconiformes , Malaria, Avian/mortality , Plasmodium/isolation & purification , Strigiformes , Animals , Antimalarials/therapeutic use , Chloroquine/therapeutic use , Italy/epidemiology , Malaria, Avian/drug therapy , Malaria, Avian/parasitology
11.
J Thromb Haemost ; 14(3): 421-6, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26711899

ABSTRACT

The term 'biosimilars' is used to qualify products developed to be similar to an original biological drug. Biosimilars are much more complicated to develop than a generic version of small-molecule drugs and this is especially true for low-molecular-weight heparins (LMWHs). Evidence on the antithrombotic management of acute coronary syndromes (ACS) showed that the introduction into the market of biosimilars approved on the basis of simple biological criteria, without robust data from comparative clinical trials, may be hazardous. Moreover, the mixtures of LMWH polysaccharide chains, some immunoallergic properties and potential contamination during the extraction process raise safety concerns. As was the case for the biosimilar erythropoietin, there is the risk that only copies of the most commercially successful LMWHs will be marketed, thus jeopardizing the 'biodiversity' now ensured by the presence of several LMWHs, each with unique features that support the use of an individual LMWH as first-choice therapy in certain categories of patients.


Subject(s)
Anticoagulants/pharmacokinetics , Biosimilar Pharmaceuticals/pharmacokinetics , Drug Discovery/methods , Drug Industry , Economic Competition , Heparin, Low-Molecular-Weight/pharmacokinetics , Anticoagulants/adverse effects , Anticoagulants/economics , Biosimilar Pharmaceuticals/adverse effects , Biosimilar Pharmaceuticals/economics , Drug Costs , Drug Discovery/economics , Drug Industry/economics , Heparin, Low-Molecular-Weight/adverse effects , Heparin, Low-Molecular-Weight/economics , Humans , Male , Patient Safety , Risk Assessment , Risk Factors , Therapeutic Equivalency
12.
Transbound Emerg Dis ; 62(3): 229-32, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25773737

ABSTRACT

In this work, we identified for the first time hepatitis E virus (HEV) in a pet house rabbit, an adult 7 years old female of domestic rabbit (Oryctolagus cuniculus). Importantly, the resulting phylogenetic tree showed that the HEV strain identified in the pet house rabbit was closely related to a human HEV sequence; this finding reawakens concerns regarding the zoonotic risk represented by HEV in animals and expands to house rabbit the spectrum of potential source of infection for humans. Potential for domestic transmission of HEV to humans should be taken into account.


Subject(s)
Animals, Domestic/virology , Hepatitis E virus/isolation & purification , Hepatitis E/veterinary , Rabbits , Zoonoses/virology , Animals , Base Sequence , Disease Vectors , Female , Hepatitis E/transmission , Hepatitis E/virology , Hepatitis E virus/classification , Hepatitis E virus/genetics , Humans , Italy , Phylogeny , Zoonoses/transmission
13.
Res Vet Sci ; 99: 196-8, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25660399

ABSTRACT

Spontaneous odontogenic tumors are neoplasms characterized by a mixed odontogenic ectomesenchymal and odontogenic epithelial origin; they are rare in both humans and animals. A 3-year-old male Alpine Chamois (Rupicapra rupicapra) was found dead in north-west Italy, and was referred for the necropsy to the Department of Veterinary Sciences of the University of Turin (Italy). At the external examination a 10 × 8 cm, exophytic, red-pink, smooth, firm and ulcerated mass was observed on the inferior lip. Histologically the tumor was characterized by spindle shaped cells arranged in bundles in an abundant hyaline matrix. Multifocal and rare chords of odontogenic epithelium mixed with rare melanocytes that penetrate the neoplasia were visible. Immunohistochemistry showed a clear cytokeratin positivity of epithelial clusters. Macroscopical, histological and immunohistochemical findings were consistent with a diagnosis of locally infiltrative ameloblastic fibroma. To our best knowledge, this is the first report of this tumor in a wild ungulate and in Alpine Chamois.


Subject(s)
Ameloblastoma/veterinary , Fibroma/veterinary , Rupicapra , Ameloblastoma/etiology , Ameloblastoma/pathology , Animals , Animals, Wild , Fibroma/etiology , Fibroma/pathology , Italy , Male
14.
Vaccine ; 32(32): 4032-8, 2014 Jul 07.
Article in English | MEDLINE | ID: mdl-24907486

ABSTRACT

A major cause of salmonellosis in humans is the contamination of pork products. Infection in pigs can be controlled using bio-security programs, but they are not sufficient in countries where a high level of infection is recorded. In this context, the use of vaccines can represent a valid supplementary method of control. Recently, we have demonstrated that an attenuated strain of Salmonella enterica serovar Typhimurium (Salmonella Typhimurium ΔznuABC) is protective against systemic and enteric salmonellosis in mouse and pig infection models, candidating this strain as an oral attenuated vaccine. In this study, we compared the efficacy of this attenuated Salmonella Typhimurium strain when administered orally or parenterally. Furthermore, in order to reproduce a pseudo-natural infection model, vaccinated pigs were allocated in the same pen with animals shedding virulent Salmonella Typhimurium. Animals were monitored weekly after vaccination and contact with infected piglets. Diarrhea and ataxia were recorded and Salmonella shedding was tested individually through bacterial culture. After four weeks of cohousing, piglets were euthanized, after which lymph nodes reactivity and gross lesions of the gut sections were scored at necropsy. Organs were submitted to microbiological and histological analyses. The data reported herein show that parenterally vaccinated animals do not shed the attenuated strain, and at the same time the absence of symptoms and decrease in virulent strain shedding in feces from day 6 after challenge demonstrated protection against infection induced by virulent Salmonella Typhimurium. In conclusion, our findings suggest that this is an alternative route of Salmonella Typhimurium ΔznuABC administration, without ignoring the advantages associated with oral vaccination.


Subject(s)
Salmonella Infections, Animal/prevention & control , Salmonella Vaccines/administration & dosage , Salmonella Vaccines/immunology , Administration, Oral , Animals , Bacterial Shedding , Dose-Response Relationship, Immunologic , Feces/microbiology , Injections, Intramuscular , Salmonella typhimurium , Sus scrofa/immunology , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunology
15.
Dis Aquat Organ ; 107(1): 31-6, 2013 Nov 25.
Article in English | MEDLINE | ID: mdl-24270021

ABSTRACT

Nine striped dolphins Stenella coeruleoalba and 1 bottlenose dolphin Tursiops truncatus stranded along the Ligurian Sea coast of Italy were necropsied between February 2011 and April 2012. Macroscopic and histological findings were observed in the hearts of all animals and included saccular aneurysms of the pulmonary trunk (n = 3), cirsoid aneurysms (n = 1), right ventricular dilation (n = 1) associated with hypoplasia of the tricuspid chordae (n = 1), valvular fibrosis (n = 3), mitral leaflet thickening (n = 1), left ventricular hypertrophy (n = 1), lymphocytic myocarditis (n =1), and Lambl's excrescences (n = 4). To our best knowledge Lambl's excrescences, aneurysm of the pulmonary trunk, and cirsoid aneurysms have not previously been described in marine mammals, and some of these findings should be taken into account as possible causes of dolphin morbidity, mortality, and stranding.


Subject(s)
Bottle-Nosed Dolphin , Heart Diseases/veterinary , Stenella , Animals , Arteries , Female , Heart Diseases/epidemiology , Heart Diseases/pathology , Italy , Male , Mediterranean Sea/epidemiology , Myocardium/pathology
17.
Res Vet Sci ; 95(2): 569-71, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23623757

ABSTRACT

A wild Beech Marten (Martes foina), was referred for necropsy to the Department of Animal Pathology of the University of Turin (Italy). At gross examination, whitish and firm masses, 10-mm in diameter, were found on the heart and in the kidney. Spleen showed lighter color and greater consistency, and the cut surface of the liver appeared scattered with whitish-yellow coalescing foci homogeneously distributed. Amyloid deposits were present in the perivascular and intercellular spaces of the visceral organs, such as the heart, liver, and kidneys. Amyloid stained positively with Congo red with and without 5% potassium permanganate pretreatment and showed green birefringence observable under polarized light. A diagnosis of systemic AL amyloidosis was made. This is the first description of systemic AL amyloidosis in a wild Stone Marten.


Subject(s)
Amyloidosis/veterinary , Mustelidae , Amyloidosis/classification , Amyloidosis/pathology , Animals , Female
18.
Eur Rev Med Pharmacol Sci ; 16(14): 1999-2005, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23242729

ABSTRACT

Bilastine is a new H1 antagonist with no sedative side effects, no cardiotoxic effects, and no hepatic metabolism. In addition, bilastine has proved to be effective for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. Pharmacological studies have shown that bilastine is highly selective for the H1 receptor in both in vivo and in vitro studies, and with no apparent affinity for other receptors. The absorption of bilastine is fast, linear and dose-proportional; it appears to be safe and well tolerated at all doses levels in healthy population. Multiple administration of bilastine has confirmed the linearity of the kinetic parameters. The distribution in the brain is undetectable. The safety profile in terms of adverse effects is very similar to placebo in all Phase I, II and III clinical trials. Bilastine (20 mg), unlike cetirizine, does not increase alcohol effects on the CNS. Bilastine 20 mg does not increase the CNS depressant effect of lorazepam. Bilastine 20 mg is similar to placebo in the driving test. Therefore, it meets the current criteria for medication used in the treatment of allergic rhinitis and urticaria.


Subject(s)
Benzimidazoles/therapeutic use , Conjunctivitis, Allergic/drug therapy , Histamine H1 Antagonists, Non-Sedating/therapeutic use , Piperidines/therapeutic use , Rhinitis, Allergic, Perennial/drug therapy , Rhinitis, Allergic, Seasonal/drug therapy , Urticaria/drug therapy , Animals , Automobile Driving , Benzimidazoles/administration & dosage , Benzimidazoles/adverse effects , Benzimidazoles/pharmacokinetics , Drug Interactions , Histamine H1 Antagonists, Non-Sedating/administration & dosage , Histamine H1 Antagonists, Non-Sedating/adverse effects , Histamine H1 Antagonists, Non-Sedating/pharmacokinetics , Humans , Piperidines/administration & dosage , Piperidines/adverse effects , Piperidines/pharmacokinetics , Rhinitis, Allergic , Treatment Outcome , Wakefulness/drug effects
19.
Eur Rev Med Pharmacol Sci ; 16(5): 569-74, 2012 May.
Article in English | MEDLINE | ID: mdl-22774395

ABSTRACT

BACKGROUND: The extract of Serenoa repens is the phytopharmaceutical product most often used for the treatment of urological symptoms associated with benign prostatic hyperplasia (BPH). Several extracts are commercially available but extraction processes vary between manufacturers and thus not all these products are equivalent in terms of active ingredient content and composition of preparations. AIM: As there is a paucity of comparative studies, we compared the activity of different extracts of Serenoa repens widely available on the world market. MATERIALS AND METHODS: Beltrax Uno, Permicaps, Permixon, Prostadyn, Prostagutt, Prostamen, Prostamol Uno, ProstaX, Urocaps and Urogutt were assayed for 5-alpha-reductase activity on 10 day fibroblasts and epithelial cells cocultures. Human fibroblast growth factor (hFGF)-induced-proliferation inhibition was also assayed. RESULTS: As to extract activity, differences were observed between the tested extracts, but all were able to inhibit 5-a-reductase types I and II isoenzymes (5alphaR-I and 5alphaR-II) as well as fibroblast proliferation. CONCLUSIONS: Extract potency differs between products and so does proliferation inhibition potency. Quantitative and qualitative variations in the active ingredient are likely to account for these differences.


Subject(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase/metabolism , 5-alpha Reductase Inhibitors/pharmacology , Cell Proliferation/drug effects , Plant Extracts/pharmacology , Prostate/drug effects , Prostatic Hyperplasia/drug therapy , 5-alpha Reductase Inhibitors/standards , Cells, Cultured , Coculture Techniques , Dose-Response Relationship, Drug , Epithelial Cells/drug effects , Epithelial Cells/enzymology , Fibroblast Growth Factors/metabolism , Fibroblasts/drug effects , Fibroblasts/enzymology , Humans , Male , Plant Extracts/standards , Prostate/enzymology , Prostate/pathology , Prostatic Hyperplasia/enzymology , Prostatic Hyperplasia/pathology , Serenoa
20.
J Wildl Dis ; 47(4): 1040-2, 2011 Oct.
Article in English | MEDLINE | ID: mdl-22102681

ABSTRACT

We describe a diffuse, multicentric, large B-cell lymphoma in a wild boar (Sus scrofa) involving the abdomen, head, and nose and invading the frontal leptomeninges. The tumor was predominantly composed of dense, basophilic, round-to-polygonal cells. Immunohistochemistry for CD79 and Ki-67 was positive in all masses.


Subject(s)
Lymphoma, B-Cell/veterinary , Sus scrofa , Swine Diseases/diagnosis , Animals , Immunohistochemistry/veterinary , Lymphoma, B-Cell/diagnosis , Male , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...